PT2076244T - Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos - Google Patents

Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos

Info

Publication number
PT2076244T
PT2076244T PT78735222T PT07873522T PT2076244T PT 2076244 T PT2076244 T PT 2076244T PT 78735222 T PT78735222 T PT 78735222T PT 07873522 T PT07873522 T PT 07873522T PT 2076244 T PT2076244 T PT 2076244T
Authority
PT
Portugal
Prior art keywords
lipid
compositions
preparation
methods
aqueous systems
Prior art date
Application number
PT78735222T
Other languages
English (en)
Inventor
M Ali Shoukath
U Ahmad Moghis
Ahmad Ateeq
Ahmad Imran
Sheikh Saifuddin
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of PT2076244T publication Critical patent/PT2076244T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT78735222T 2006-10-10 2007-10-10 Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos PT2076244T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85044606P 2006-10-10 2006-10-10
US95702207P 2007-08-21 2007-08-21

Publications (1)

Publication Number Publication Date
PT2076244T true PT2076244T (pt) 2017-03-09

Family

ID=39864519

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78735222T PT2076244T (pt) 2006-10-10 2007-10-10 Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos

Country Status (10)

Country Link
US (2) US20160310600A1 (pt)
EP (1) EP2076244B1 (pt)
JP (2) JP5917789B2 (pt)
CA (1) CA2666322C (pt)
DK (1) DK2076244T3 (pt)
ES (1) ES2617747T3 (pt)
HU (1) HUE031951T2 (pt)
PL (1) PL2076244T3 (pt)
PT (1) PT2076244T (pt)
WO (1) WO2008127358A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
JP2010510327A (ja) 2006-11-21 2010-04-02 ジャイナ ファーマシューティカルズ，インコーポレーテッド エンドキシフェンの方法および組成物
EP2344198B1 (en) * 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Lipid based pharmaceutical preparations for topical application
AU2010261342A1 (en) 2009-06-19 2012-01-19 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
US20170340563A1 (en) * 2009-09-23 2017-11-30 Curirx Inc. Methods for the Preparation of Liposomes Comprising Drugs
WO2011038068A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
LT2661253T (lt) 2011-01-04 2017-05-25 Archivel Farma, Sl Liposomų kompozicija, tinkama tuberkuliozės gydymui arba prevencijai
IN2014MN01594A (pt) 2012-01-12 2015-05-08 Archivel Farma Sl
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
JP2016535734A (ja) * 2013-10-21 2016-11-17 エンザイモテック リミテッド コリン及びその誘導体を含む組成物、その用途及び調製方法
CN105658203B (zh) * 2013-11-08 2021-03-16 株式会社活效制药 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂
EP3150196A1 (en) * 2015-09-30 2017-04-05 Sun Pharma Advanced Research Company Ltd Process for the preparation of unilamellar liposomal composition
CN113181118A (zh) * 2016-01-07 2021-07-30 健康科学西部大学 用于治疗膀胱癌的制剂
JP7041961B2 (ja) * 2016-04-08 2022-03-25 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ ヒト嚢胞性線維症肺上皮における気道表面の生理機能の小分子介在性回復
US20170290852A1 (en) * 2016-04-08 2017-10-12 Wisconsin Alumni Research Foundation Micelle formulations of amphotericin b
KR20200015457A (ko) * 2017-02-21 2020-02-12 아이코 테라퓨틱스 인코포레이티드 암포테리신 b의 고형 경구 제형
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
JP2021504433A (ja) * 2017-11-30 2021-02-15 シルパ メディケア リミテッドＳｈｉｌｐａ Ｍｅｄｉｃａｒｅ Ｌｉｍｉｔｅｄ 高薬物ローディングを有するドセタキセルリポソーム注射剤の組成物
EP3603682A1 (en) * 2018-08-03 2020-02-05 Alchilife S.r.l. Tablet with an antimycotic agent, medical device and method for preserving harvested corneas
US11857680B2 (en) * 2018-11-26 2024-01-02 Shilpa Medicare Limited Composition of docetaxel liposomal injection with high drug loading
EP4164415A1 (en) * 2020-06-15 2023-04-19 University of Utah Research Foundation Retinal bioavailability of synthetic very-long-chain polyunsaturated fatty acids
WO2022081479A2 (en) * 2020-10-12 2022-04-21 Durect Corporation Crystalline sodium cholesteryl sulfonate
WO2022081481A2 (en) * 2020-10-12 2022-04-21 Durect Corporation Crystalline sodium cholesteryl sulfate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782310A (en) * 1980-11-11 1982-05-22 Tanabe Seiyaku Co Ltd Production of liposome preparation
JPS5782311A (en) * 1980-11-11 1982-05-22 Tanabe Seiyaku Co Ltd Production of liposome preparation
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CA2095627C (en) * 1990-11-06 1999-01-05 Junzo Seki Stable lyophilized fatty emulsions and a process for the production thereof
DE4207481A1 (de) * 1992-03-10 1993-09-16 Bayer Ag Liposomale wirkstoff-formulierungen und verfahren zu ihrer herstellung
CA2205500A1 (en) * 1994-11-18 1996-05-30 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
MXPA03003401A (es) * 2000-10-16 2004-06-30 Neopharm Inc Formulacion liposomica de mitoxantrona.
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US20050214378A1 (en) * 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
EP1684716A4 (en) * 2003-11-05 2009-04-22 Univ Australian DISPERSIONS AND METHODS OF PREPARATION
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method

Also Published As

Publication number Publication date
WO2008127358A3 (en) 2008-12-24
US20160310600A1 (en) 2016-10-27
ES2617747T3 (es) 2017-06-19
JP5917789B2 (ja) 2016-05-18
JP2010505965A (ja) 2010-02-25
CA2666322A1 (en) 2008-10-23
PL2076244T3 (pl) 2017-05-31
EP2076244A4 (en) 2013-01-09
DK2076244T3 (en) 2017-02-27
WO2008127358A2 (en) 2008-10-23
CA2666322C (en) 2013-04-23
EP2076244B1 (en) 2016-12-07
HUE031951T2 (en) 2017-08-28
EP2076244A2 (en) 2009-07-08
US20200345849A1 (en) 2020-11-05
JP2016041704A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
EP2076244A4 (en) AQUEOUS SYSTEMS FOR THE PREPARATION OF LIPID-BASED PHARMACEUTICAL COMPOUNDS AND THEIR COMPOSITIONS, METHODS AND USES
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
EP2078731A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
EP1841761A4 (en) Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL196280A0 (en) Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them
ZA200901702B (en) Self-preserved aqueous pharmaceutical compositions
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
IL198847A0 (en) New process for the preparation of 2-imino-thiazolidin-4-one derivatives
ME02689B (me) Novi kristalni oblik iii agomelatina, postupak za njegovu pripremu i farmaceutski preparati istog
IL197877A (en) Uses of aminomethyl-4-imidazole derivatives for the preparation of medications and medications containing them
HK1134902A1 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
ZA201007610B (en) Processes for the preparation of benzo-fused dioxin derivatives
HUP0600293A2 (en) Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions
IL214028A (en) A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
IL190230A0 (en) Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
IL201912A0 (en) Aqueous pharmaceutical composition